Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad26.RSV.preF RSV human challenge study in healthy adults
2017-003194-33Phase 2Completed
- Sponsor
- Johnson & Johnson
- Start
- Aug 2017
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing Ad26.RSV.preF with Placebo (2 arms). Primary endpoint: Viral load area under the curve. Started Aug 2017; status: completed.
02
Drugs
Ad26.RSV.preF
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2017-003194-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003194-33.